173 related articles for article (PubMed ID: 37030295)
41. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies.
Tantawy SI; Sarkar A; Hubner S; Tan Z; Wierda WG; Eldeib A; Zhang S; Kornblau S; Gandhi V
Clin Cancer Res; 2023 Jan; 29(2):446-457. PubMed ID: 36346691
[TBL] [Abstract][Full Text] [Related]
42. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P; Yang JW; Yang VW; Bialkowska AB
Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
[TBL] [Abstract][Full Text] [Related]
43. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
44. Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
Lu C; Yang D; Sabbatini ME; Colby AH; Grinstaff MW; Oberlies NH; Pearce C; Liu K
BMC Cancer; 2018 Feb; 18(1):149. PubMed ID: 29409480
[TBL] [Abstract][Full Text] [Related]
45. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
[TBL] [Abstract][Full Text] [Related]
46. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
47. Involvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor.
Amada K; Hijiya N; Ikarimoto S; Yanagihara K; Hanada T; Hidano S; Kurogi S; Tsukamoto Y; Nakada C; Kinoshita K; Hirashita Y; Uchida T; Shin T; Yada K; Hirashita T; Kobayashi T; Murakami K; Inomata M; Shirao K; Aoki M; Takekawa M; Moriyama M
Cancer Sci; 2023 May; 114(5):2189-2202. PubMed ID: 36694355
[TBL] [Abstract][Full Text] [Related]
48. BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer.
Habata S; Iwasaki M; Sugio A; Suzuki M; Tamate M; Satohisa S; Tanaka R; Saito T
Int J Oncol; 2016 Jul; 49(1):402-10. PubMed ID: 27120977
[TBL] [Abstract][Full Text] [Related]
49. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
[TBL] [Abstract][Full Text] [Related]
50. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
[TBL] [Abstract][Full Text] [Related]
51. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.
Santana-Codina N; Roeth AA; Zhang Y; Yang A; Mashadova O; Asara JM; Wang X; Bronson RT; Lyssiotis CA; Ying H; Kimmelman AC
Nat Commun; 2018 Nov; 9(1):4945. PubMed ID: 30470748
[TBL] [Abstract][Full Text] [Related]
52. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
[TBL] [Abstract][Full Text] [Related]
53. USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy.
Ma T; Chen W; Zhi X; Liu H; Zhou Y; Chen BW; Hu L; Shen J; Zheng X; Zhang S; Zhang B; Li H; Liang T
Cancer Lett; 2018 Nov; 436():129-138. PubMed ID: 30118840
[TBL] [Abstract][Full Text] [Related]
54. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.
Ozkan-Dagliyan I; Diehl JN; George SD; Schaefer A; Papke B; Klotz-Noack K; Waters AM; Goodwin CM; Gautam P; Pierobon M; Peng S; Gilbert TSK; Lin KH; Dagliyan O; Wennerberg K; Petricoin EF; Tran NL; Bhagwat SV; Tiu RV; Peng SB; Herring LE; Graves LM; Sers C; Wood KC; Cox AD; Der CJ
Cell Rep; 2020 Jun; 31(11):107764. PubMed ID: 32553168
[TBL] [Abstract][Full Text] [Related]
55. Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 Degradation.
He M; Qiao Z; Wang Y; Kuai Q; Li C; Wang Y; Jiang X; Wang X; Li W; He M; Ren S; Yu Q
PLoS One; 2016; 11(11):e0166896. PubMed ID: 27875574
[TBL] [Abstract][Full Text] [Related]
56. USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer.
Hou P; Ma X; Yang Z; Zhang Q; Wu CJ; Li J; Tan L; Yao W; Yan L; Zhou X; Kimmelman AC; Lorenzi PL; Zhang J; Jiang S; Spring D; Wang YA; DePinho RA
Genes Dev; 2021 Oct; 35(19-20):1327-1332. PubMed ID: 34531315
[TBL] [Abstract][Full Text] [Related]
57. K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
Wei F; Liu Y; Bellail AC; Olson JJ; Sun SY; Lu G; Ding L; Yuan C; Wang G; Hao C
Cancer Lett; 2012 Sep; 322(1):58-69. PubMed ID: 22342683
[TBL] [Abstract][Full Text] [Related]
58. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
[TBL] [Abstract][Full Text] [Related]
59. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.
Papademetrio DL; Lompardía SL; Simunovich T; Costantino S; Mihalez CY; Cavaliere V; Álvarez É
Target Oncol; 2016 Apr; 11(2):183-95. PubMed ID: 26373299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
